ArticleFrontiers in veterinary science2020
Novel
Article in Frontiers in veterinary science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Adenosine from high-fat-diet-tolerant monkey-derived Limsolactobacillus reuteri MacFasB02 modulates cholesterol metabolism to alleviate hyperlipidemia and inflammation.NPJ science of food · 2026Article
- Updated Insights into Probiotic Interventions for Metabolic Syndrome: Mechanisms and Evidence.Probiotics and antimicrobial proteins · 2026Review
- N-3 highly unsaturated fatty acids combined with pro-biotics or post-biotics synergistically alleviate dyslipidemia in rats exposed to chronic mild stress.Nutrition research and practice · 2025Article
- Research Progress on the Mechanism of Action and Screening Methods of Probiotics for Lowering Blood Lipid Levels.Foods (Basel, Switzerland) · 2025Review
- Microbiome, Potential Therapeutic Agents: New Players of Obesity Treatment.Journal of microbiology and biotechnology · 2025Review
- The Impact ofMicroorganisms · 2024Review
- Article
- Accounting for the health risk of probiotics.Heliyon · 2024Review
- Assessment of Two Potential Probiotic Strains As Anti-Obesity Supplements Under High-Fat Feeding Conditions.Probiotics and antimicrobial proteins · 2023Article
- Exploring a Possible Link between the Fecal Microbiota and the Production Performance of Pigs.Veterinary sciences · 2022Article
- Liver Transcriptome and Gut Microbiome Analysis Reveals the Effects of High Fructose Corn Syrup in Mice.Frontiers in nutrition · 2022Article
- Article
- Therapeutic and Improving Function of Lactobacilli in the Prevention and Treatment of Cardiovascular-Related Diseases: A Novel Perspective From Gut Microbiota.Frontiers in nutrition · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal probiotics are a primary focus area of current medical research. Probiotics such as bifidobacteria and lactobacilli can positively impact obesity and other metabolic diseases by directly or indirectly affecting lipid metabolism. However, the precise mechanisms of these effects remain unclear. In our previous work, the novel strain
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.